Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: interactions with antihypertensive therapy (Q33545592)

27 July 2017

1 reference

title

Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: interactions with antihypertensive therapy (English)

1 reference

27 July 2017

main subject

prostatic hypertrophy

1 reference

Tewari A

1

1 reference

27 July 2017

Narayan P

series ordinal

2

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

27 July 2017

1 reference

27 July 2017

volume

53

1 reference

27 July 2017

issue

3 Suppl 3a

1 reference

27 July 2017

page(s)

14-20; discussion 41-2

1 reference

Relationship of Symptoms of Prostatism to Commonly Used Physiological and Anatomical Measures of the Severity of Benign Prostatic Hyperplasia

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

International comparison of the community prevalence of symptoms of prostatism in four countries.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Epidemiology and prevention of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Withdrawal of long-term diuretic medication in elderly patients: a double blind randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

The costs of interrupting antihypertensive drug therapy in a Medicaid population.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Overview of alpha-blocker therapy for benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Regulation of prostatic smooth muscle contractility by intracellular second messengers: implications for the conservative treatment of benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Effects of specific alpha-adrenoceptive agents on extraneuronal uptake (uptake2) of isoproterenol in perfused rat heart

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Prostatic alpha 1-adrenoceptors and uroselectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Effects of selective and nonselective alpha-1-adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Alpha 1-adrenoceptors and calcium sources in adrenergic neurogenic contractions of rat vas deferens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Alpha 1-adrenoceptors: the ability of various agonists and antagonists to discriminate between two distinct [3H]prazosin binding sites

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Current status of research on prostate-selective alpha 1-antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Adverse effects of alpha 1-adrenergic blocking drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Pharmacological analysis of postjunctional alpha-adrenoceptors mediating contractions to (-)-noradrenaline in the rabbit isolated lateral saphenous vein can be explained by interacting responses to simultaneous activation of alpha 1- and alpha 2-adr

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Effects of Prazosin in Patients with Benign Prostatic Obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Benign prostatic hyperplasia. Current pharmacological treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Prazosin in the Treatment of Prostatic Obstruction A Placebo-controlled Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Tamsulosin : A Review of its Pharmacological Properties and Therapeutic Potential in the Management of Symptomatic Benign Prostatic Hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

[Urodynamic evaluation of alpha-1 blocker tamsulosin on benign prostatic hyperplasia using pressure-flow study]

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. The Kobe University YM617 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Continuing advances in hypertension: the Joint National Committee's fifth report

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Pharmacological properties of combination therapies for hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Use of Digoxin, Diuretics, Beta Blockers, Angiotensin‐Converting Enzyme Inhibitors, and Calcium Channel Blockers in Older Patients in an Academic Hospital‐Based Geriatrics Practice

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Treatment of hypertension in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Choice of initial therapy for hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Current status of diuretics, beta-blockers, alpha-blockers, and alpha-beta-blockers in the treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Calcium channel blockers and cardiac mortality in the treatment of hypertension: a report from the Department of Health Hypertension Care Computing Project (DHCCP).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

A comparative review of the adverse effects of calcium antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Calcium channel blockers and hypertension: evolving perspective--1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Calcium channel blockers: summary and safety issues

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

High blood pressure and calcium antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Current position of calcium antagonists in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Nisoldipine coat-core. A review of its pharmacology and therapeutic efficacy in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Antihypertensive therapy. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and calcium antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Combination treatment in hypertension: the VeraTran Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Adverse metabolic effects of antihypertensive drugs. Implications for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta-blocker.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Angiotensin II receptor antagonists: the prototype losartan

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Experience with angiotensin II antagonists in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Managing hypertension in the elderly: dispelling the myths.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

Evolution of the treatment of hypertension from the 1940s to JNC V.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

New staging system of the fifth Joint National Committee report on the detection, evaluation, and treatment of high blood pressure (JNC-V) alters assessment of the severity and treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900534-2

7 January 2021

10.1016/S0090-4295(98)00534-2

Identifiers

DOI

1 reference

27 July 2017

1 reference